These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8070290)

  • 21. Serum hyaluronan and laminin level in children with chronic hepatitis B during long-term lamivudine treatment.
    Lebensztejn DM; Skiba E; Sobaniec-Lotowska ME; Kaczmarski M
    Hepatogastroenterology; 2007; 54(75):834-8. PubMed ID: 17591074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship of serum iron and ferritin with the indicators for hepatic fibrosis].
    Huang CW; Bai L; Cai JJ; Guo W; Lan L
    Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):466-8. PubMed ID: 12754132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin.
    Murawaki Y; Kusakabe Y; Hirayama C
    Hepatology; 1991 Dec; 14(6):1167-73. PubMed ID: 1683640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between staging of hepatic fibrosis and the levels of serum biochemistry.
    Xu GG; Luo CY; Wu SM; Wang CL
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):246-8. PubMed ID: 14612277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
    Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
    Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Screening and evaluation of non-invasive diagnosis markers for compensated liver cirrhosis in patients with chronic hepatitis B].
    Chen YP; Feng XR; Dai L; Ding HB; Zhang L
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):225-7. PubMed ID: 12716522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
    Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
    Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases].
    Tomihira M
    Fukuoka Igaku Zasshi; 1991 Jan; 82(1):21-30. PubMed ID: 1708742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum hyaluronic acid as a marker of hepatic fibrosis.
    Khan JA; Khan FA; Dilawar M; Ijaz A; Khan NA; Mehmood T
    J Coll Physicians Surg Pak; 2007 Jun; 17(6):323-6. PubMed ID: 17623578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Quantitative analysis of serum hyaluronic acid and its application in liver disease].
    Qiang Y; Wang J; Sun W
    Zhonghua Yu Fang Yi Xue Za Zhi; 1995 Jan; 29(1):21-3. PubMed ID: 7600884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concentration of serum laminin and type IV collagen in liver diseases assayed by a sandwich enzyme-immunoassay using monoclonal antibodies.
    Yokoya Y; Iwata K; Muragaki Y; Shiota C; Morimoto Y; Inoue M; Itoh H; Nishioka S; Ooshima A
    Clin Chim Acta; 1992 Sep; 210(1-2):109-18. PubMed ID: 1330375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Determination and significance of serum markers for fibrosis in patients with chronic hepatitis].
    Cai W; Zheng M; Weng H; Liu R
    Zhonghua Nei Ke Za Zhi; 2001 Jul; 40(7):448-51. PubMed ID: 11798612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B.
    Lebensztejn DM; Kaczmarski M; Sobaniec-Łotowska M; Bauer M; Voelker M; Schuppan D
    Hepatology; 2004 Mar; 39(3):868-9. PubMed ID: 14999715
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical implications of measurement of serum nuclear matrix protein levels in patients with liver disease.
    Shimizu Y; Nakano I; Katano Y; Shimizu H; Fukuda Y
    Hepatogastroenterology; 2005; 52(66):1809-13. PubMed ID: 16334782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of extracellular matrix in acute pancreatitis.
    Löhr M; Hummel F; Martus P; Cidlinsky K; Kröger JC; Hahn EG; Oesterling C; Emmrich J; Schuppan D; Liebe S
    Hepatogastroenterology; 1999; 46(30):3263-70. PubMed ID: 10626198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical and pathological study on liver fibrosis in viral hepatitis].
    Xin S; Mao Y; Wang L; Li Y; Li L; Yu H; Zhao M; Zhang S; Wang S; Wang X; Chen L; Zhou X; Zhou Y; Zou Z; Tang S; Huangpu Y; Zhang L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):240-3. PubMed ID: 15617338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.
    Lebensztejn DM; Wierzbicka A; Socha P; Pronicki M; Skiba E; Werpachowska I; Kaczmarski M
    Acta Biochim Pol; 2011; 58(4):563-6. PubMed ID: 22140659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Determination of serum procollagen-III peptide in chronic liver diseases. Clinical usefulness].
    Pagani A; Zigliani P; Pranzo A; Galante T
    Minerva Med; 1992 Nov; 83(11):715-20. PubMed ID: 1461542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease.
    Murawaki Y; Yamada S; Ikuta Y; Kawasaki H
    J Hepatol; 1999 Jun; 30(6):1090-8. PubMed ID: 10406188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of interferon alpha on the serum fibrosis markers of chronic hepatitis C patients].
    Zhang BB; Zhu SH; Cai WM
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):622-3. PubMed ID: 14572344
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.